<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160117026069N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-26</date_registration>
      <primary_sponsor>Karaj University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of probiotic use in chronic functional constipation</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of probiotic use (Lactobacillus reuteri) in children between ages of 2 and 14  with chronic functional constipation; Double-blind randomized clinical trial.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67788</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Sealed envelopes are considered as the number of patients, whose content determines which group each person belongs to. One of these envelopes is selected for each patient by lottery, and then this envelope is opened and the allocation of the patient will be determined after opening the envelopes, Blinding description: Only the main researcher of the research is aware of the assignment of the codes, and until the end of the research, it will not be clear for the patient, the treating physician and those who evaluate the results, whether A or B is a placebo or the studied probiotic combination.</study_design>
      <phase>3</phase>
      <hc_freetext>Functional constipation.</hc_freetext>
      <i_freetext>Intervention 1: Pidrolax drug (Pidrolax 4000 powder, 70g packets, made by Sepidaj Daru Company) is prescribed according to the following method: Children's dose 2 to 6 years old: 5 grams (one tablespoon) dissolved in a quarter of a glass of water or fruit juice and preferably eaten in the morning on an empty stomach. Children from 7 to 14 years old: 10 grams (one tablespoon) dissolved in half a glass of water or fruit juice and preferably eaten in the morning on an empty stomach. The patient should be repeated, and then in the following days, according to the patient's response status, the drug dose should be adjusted so that he has at least one soft stool per day. In case of no response despite taking the maximum dose of Pidrolox, the situation should be reported to the project manager. To take the necessary measures to correct the treatment. The main drug under investigation is the probiotic Lactobacillus roteri (Roteflor powder, produced by Farabiotic Company) in the form of one-gram sachets containing 300 mg of lyophilized active cells (equivalent to 8x10⁸ CFU), which according to the doctor's prescription, one sachet per day in half a glass of cold liquid or yogurt It is solved and consumed. In the first session, complete explanations about the treatment process, how to take medicines, diet, necessary behavioral training and danger signs are given to the parents, and the patient's information and history are recorded. After the start of the treatment, in the weeks 1st, 3rd, 5th and 7th, during a phone call or in person (according to the discretion of the patient's parents), the patient's condition is measured and the course of the symptoms is recorded, and the necessary corrections are applied in the way of implementing the treatment or any side issues that arise. The treatment is carried out for 7 weeks, and the parents are advised to avoid stopping or changing the medication without coordinating with the doctor. If the child has not had a stool for three consecutive days, life-saving treatment with liquid paraffin medicine with a dose of 1-3 cc /kg will be used. Intervention 2: Pidrolax drug (Pidrolax 4000 powder, 70g packets, made by Sepidaj Daru Company) is prescribed according to the following method: Children's dose 2 to 6 years old: 5 grams (one tablespoon) dissolved in a quarter of a glass of water or fruit juice and preferably eaten in the morning on an empty stomach. Children from 7 to 14 years old: 10 grams (one tablespoon) dissolved in half a glass of water or fruit juice and preferably eaten in the morning on an empty stomach. The patient should be repeated, and then in the following days, according to the patient's response status, the drug dose should be adjusted so that he has at least one soft stool per day. In case of no response despite taking the maximum dose of Pidrolox, the situation should be reported to the project manager. To take the necessary measures to correct the treatment. The control group will receive placebo which is similar to the main drug, a powder produced by Farabiotic Company in the form of one-gram sachets which according to the doctor's prescription, one sachet per day in half a glass of cold liquid or yogurt It is solved and consumed. In the first session, complete explanations about the treatment process, how to take medicines, diet, necessary behavioral training and danger signs are given to the parents, and the patient's information and history are recorded. After the start of the treatment, in the weeks 1st, 3rd, 5th and 7th, during a phone call or in person (according to the discretion of the patient's parents), the patient's condition is measured and the course of the symptoms is recorded, and the necessary corrections are applied in the way of implementing the treatment or any side issues that arise. The treatment is carried out for 7 weeks, and the parents are advised to avoid stopping or changing the medication without coordinating with the doctor. If the child has not had a stool for three consecutive days, life-saving treatment with liquid paraffin medicine with a dose of 1-3 cc /kg will be used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All of the participans' individual data

When:
Access starts 6 months after results are published

To whom:
All researchers working in academic and scientific institutions and people working in the industry

Conditions:
If a request with this theme is received, a decision will be made with the opinion of the research team.

Where to obtain:
To the project manager, Dr. Kyomarth Pourrostami

How to obtain:
After submitting the request to the project manager, this request will be reviewed by a committee with the presence of all the people involved in the project, and then if the committee gives a positive answer, the data will be provided to the applicant.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fereshteh Ansari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Beheshti Ave., Hesarak</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3197619751</zip>
        <telephone>+98 26 3405 0400</telephone>
        <email>fereshtehansari66@gmail.com</email>
        <affiliation>Razi Vaccine and Serum Research Institute</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Kumars Pourrostami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Medicine, West end of Bu-Ali, Nobovat Sq.</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3149969415</zip>
        <telephone>+98 26 3447 8835</telephone>
        <email>dr.porrostami1975@gmail.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Suffering from functional constipation according to Rome IV criteria
Age 2 to 14 years
Enforceability of orders by the child's parents</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>14 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Children with organic causes of constipation including celiac disease, intestinal obstruction, hypothyroidism, anorectal malformation, CF
Serious chronic health problems that affect the child's ability to participate in the study, such as metabolic, heart, kidney, and liver diseases
Unwanted weight loss equal to or more than 5% of the current weight during the last three months
Gastrointestinal bleeding
Recurrent or unexplained fever
History of abdominal surgery including gastrointestinal surgery, except for appendix removal or hernia repair
Simultaneous use of drugs that affect the movements of the digestive system
History of increased sensitivity or allergy to experimental drugs
Diagnosis of autism symptoms
Severe mental problems such as bipolar disorder, schizophrenia, and severe depression
Use of (SNS) or antegrade enemas during cecostomy or appendicostomy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Pidrolax drug (Pidrolax 4000 powder, 70g packets, made by Sepidaj Daru Company) is prescribed according to the following method: Children's dose 2 to 6 years old: 5 grams (one tablespoon) dissolved in a quarter of a glass of water or fruit juice and preferably eaten in the morning on an empty stomach. Children from 7 to 14 years old: 10 grams (one tablespoon) dissolved in half a glass of water or fruit juice and preferably eaten in the morning on an empty stomach. The patient should be repeated, and then in the following days, according to the patient's response status, the drug dose should be adjusted so that he has at least one soft stool per day. In case of no response despite taking the maximum dose of Pidrolox, the situation should be reported to the project manager. To take the necessary measures to correct the treatment. The main drug under investigation is the probiotic Lactobacillus roteri (Roteflor powder, produced by Farabiotic Company) in the form of one-gram sachets containing 300 mg of lyophilized active cells (equivalent to 8x10⁸ CFU), which according to the doctor's prescription, one sachet per day in half a glass of cold liquid or yogurt It is solved and consumed. In the first session, complete explanations about the treatment process, how to take medicines, diet, necessary behavioral training and danger signs are given to the parents, and the patient's information and history are recorded. After the start of the treatment, in the weeks 1st, 3rd, 5th and 7th, during a phone call or in person (according to the discretion of the patient's parents), the patient's condition is measured and the course of the symptoms is recorded, and the necessary corrections are applied in the way of implementing the treatment or any side issues that arise. The treatment is carried out for 7 weeks, and the parents are advised to avoid stopping or changing the medication without coordinating with the doctor. If the child has not had a stool for three consecutive days, life-saving treatment with liquid paraffin medicine with a dose of 1-3 cc /kg will be used.</i_keyword>
      <i_keyword>Pidrolax drug (Pidrolax 4000 powder, 70g packets, made by Sepidaj Daru Company) is prescribed according to the following method: Children's dose 2 to 6 years old: 5 grams (one tablespoon) dissolved in a quarter of a glass of water or fruit juice and preferably eaten in the morning on an empty stomach. Children from 7 to 14 years old: 10 grams (one tablespoon) dissolved in half a glass of water or fruit juice and preferably eaten in the morning on an empty stomach. The patient should be repeated, and then in the following days, according to the patient's response status, the drug dose should be adjusted so that he has at least one soft stool per day. In case of no response despite taking the maximum dose of Pidrolox, the situation should be reported to the project manager. To take the necessary measures to correct the treatment. The control group will receive placebo which is similar to the main drug, a powder produced by Farabiotic Company in the form of one-gram sachets which according to the doctor's prescription, one sachet per day in half a glass of cold liquid or yogurt It is solved and consumed. In the first session, complete explanations about the treatment process, how to take medicines, diet, necessary behavioral training and danger signs are given to the parents, and the patient's information and history are recorded. After the start of the treatment, in the weeks 1st, 3rd, 5th and 7th, during a phone call or in person (according to the discretion of the patient's parents), the patient's condition is measured and the course of the symptoms is recorded, and the necessary corrections are applied in the way of implementing the treatment or any side issues that arise. The treatment is carried out for 7 weeks, and the parents are advised to avoid stopping or changing the medication without coordinating with the doctor. If the child has not had a stool for three consecutive days, life-saving treatment with liquid paraffin medicine with a dose of 1-3 cc /kg will be used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Treatment of functional constipation. Timepoint: The beginning of the study (before the start of the intervention), one week later, week 3, week 5, and week 7. Method of measurement: doctor checkup.</prim_outcome>
      <prim_outcome>Abdominal pain. Timepoint: The beginning of the study (before the start of the intervention), one week later, week 3, week 5, and week 7. Method of measurement: doctor checkup.</prim_outcome>
      <prim_outcome>Side effects. Timepoint: The beginning of the study (before the start of the intervention), one week later, week 3, week 5, and week 7. Method of measurement: doctor checkup.</prim_outcome>
      <prim_outcome>Need for rescue treatment. Timepoint: The beginning of the study (before the start of the intervention), one week later, week 3, week 5, and week 7. Method of measurement: doctor checkup.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Karaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-12</approval_date>
        <contact_name>Ethics committee of Alborz University of Medical Sciences</contact_name>
        <contact_address>Saffarian Alley, Golshahr Blvd, Karaj Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
